Study of Undertreatment of Patients With Dyslipidemia in Bulgaria (CEPHEUS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01075594
First received: February 19, 2010
Last updated: September 9, 2010
Last verified: September 2010

February 19, 2010
September 9, 2010
February 2010
August 2010   (final data collection date for primary outcome measure)
The number and percentage of patients achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines [ Time Frame: 6 months - one visit only, no follow-up visits ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01075594 on ClinicalTrials.gov Archive Site
  • The number and percentage of subjects achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines for several subject subsets [ Time Frame: 6 months - one visit only, no follow-up visits ] [ Designated as safety issue: No ]
  • The number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III / 2004 updated 2004 NCEP ATP III guidelines, overall and for several subject subsets [ Time Frame: 6 months - one visit only, no follow-up visits ] [ Designated as safety issue: No ]
  • The number and percentage of subjects achieving the non HDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III/national guidelines [<130mg/dL (3,37mmol/L)], in the following sub-population: patients with fasting triglycerides >200 mg/dL [ Time Frame: 6 months - one visit only, no follow-up visits ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study of Undertreatment of Patients With Dyslipidemia in Bulgaria
Centralized Pan-Bulgarian Survey on the Undertreatment of Hypercholesterolemia

The purpose of this study is to establish the proportion of Bulgarian patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Fourth Joint European Task Force guidelines.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   None Retained
Description:

whole blood, serum

Probability Sample

Primary care clinic

Dyslipidemia
Not Provided
1
Patients with dyslipidemia on lipid lowering therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2500
August 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks
  • Signed Informed Consent

Exclusion Criteria:

  • Informed Consent not provided
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Bulgaria
 
NCT01075594
NIS-CBG-CRE-2009/1
No
MSD, AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP